BRPI0924060A8 - derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicação em terapêutica com ativadores de hif - Google Patents

derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicação em terapêutica com ativadores de hif

Info

Publication number
BRPI0924060A8
BRPI0924060A8 BRPI0924060A BRPI0924060A BRPI0924060A8 BR PI0924060 A8 BRPI0924060 A8 BR PI0924060A8 BR PI0924060 A BRPI0924060 A BR PI0924060A BR PI0924060 A BRPI0924060 A BR PI0924060A BR PI0924060 A8 BRPI0924060 A8 BR PI0924060A8
Authority
BR
Brazil
Prior art keywords
hyphen
pyrazol
activators
pyridin
therapy
Prior art date
Application number
BRPI0924060A
Other languages
English (en)
Inventor
Géraldine Manette
Jean-Michel Altenburger
Stéphane Illiano
Valérie FOSSEY
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0807474A external-priority patent/FR2940651B1/fr
Priority claimed from FR0904092A external-priority patent/FR2949466A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI0924060A2 publication Critical patent/BRPI0924060A2/pt
Publication of BRPI0924060A8 publication Critical patent/BRPI0924060A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
BRPI0924060A 2008-12-29 2009-12-24 derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicação em terapêutica com ativadores de hif BRPI0924060A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0807474A FR2940651B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
FR0904092A FR2949466A1 (fr) 2009-08-28 2009-08-28 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
PCT/FR2009/052691 WO2010076524A2 (fr) 2008-12-29 2009-12-24 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif

Publications (2)

Publication Number Publication Date
BRPI0924060A2 BRPI0924060A2 (pt) 2015-07-07
BRPI0924060A8 true BRPI0924060A8 (pt) 2015-09-29

Family

ID=42008610

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924060A BRPI0924060A8 (pt) 2008-12-29 2009-12-24 derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicação em terapêutica com ativadores de hif

Country Status (35)

Country Link
US (1) US8541455B2 (pt)
EP (1) EP2382205B1 (pt)
JP (1) JP5734870B2 (pt)
KR (1) KR20110099786A (pt)
CN (1) CN102333769B (pt)
AR (1) AR074915A1 (pt)
AU (1) AU2009334569B2 (pt)
BR (1) BRPI0924060A8 (pt)
CA (1) CA2748411A1 (pt)
CL (1) CL2011001496A1 (pt)
CO (1) CO6400141A2 (pt)
CR (1) CR20110361A (pt)
CY (1) CY1115368T1 (pt)
DK (1) DK2382205T3 (pt)
EA (1) EA019591B1 (pt)
EC (1) ECSP11011155A (pt)
ES (1) ES2481042T3 (pt)
HR (1) HRP20140680T1 (pt)
IL (1) IL213789A (pt)
MA (1) MA32976B1 (pt)
MX (1) MX2011007054A (pt)
MY (1) MY179093A (pt)
NZ (1) NZ593751A (pt)
PA (1) PA8856201A1 (pt)
PE (1) PE20120416A1 (pt)
PL (1) PL2382205T3 (pt)
PT (1) PT2382205E (pt)
SG (1) SG172803A1 (pt)
SI (1) SI2382205T1 (pt)
SM (1) SMT201400097B (pt)
TN (1) TN2011000267A1 (pt)
TW (1) TWI482763B (pt)
UY (1) UY32369A (pt)
WO (1) WO2010076524A2 (pt)
ZA (1) ZA201104783B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011007061A (es) 2008-12-29 2011-12-16 Sanofi Sa Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.
JP5902671B2 (ja) * 2011-03-31 2016-04-13 キッセイ薬品工業株式会社 ベンジルピラゾール誘導体の製造方法およびその製造中間体
CA2869130A1 (en) * 2012-03-30 2013-10-03 Daiichi Sankyo Company, Limited 4-alkanoylamino-3-pyrazolone derivatives
EP3336084B1 (en) * 2013-03-29 2021-03-17 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
DE102016223133A1 (de) 2016-11-23 2018-05-24 Deere & Company Geschwindigkeitskontrolle einer Erntemaschine
CN121085892A (zh) * 2020-03-20 2025-12-09 阿克比治疗有限公司 Phd抑制剂化合物、组合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023488A1 (de) * 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
US5750088A (en) 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ,インク. 化合物、組成物および方法
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
KR20090066297A (ko) 2006-10-16 2009-06-23 화이자 프로덕츠 인크. 치료용 피라졸릴 티에노피리딘
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
EP2148877A2 (en) 2007-05-18 2010-02-03 Bayer Schering Pharma AG Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Also Published As

Publication number Publication date
CN102333769A (zh) 2012-01-25
WO2010076524A2 (fr) 2010-07-08
KR20110099786A (ko) 2011-09-08
ES2481042T3 (es) 2014-07-29
AU2009334569A1 (en) 2011-07-21
EA201170899A1 (ru) 2012-02-28
ZA201104783B (en) 2012-09-26
JP2012513976A (ja) 2012-06-21
MY179093A (en) 2020-10-27
MX2011007054A (es) 2011-11-29
IL213789A (en) 2014-11-30
IL213789A0 (en) 2011-07-31
CN102333769B (zh) 2014-08-27
CO6400141A2 (es) 2012-03-15
US8541455B2 (en) 2013-09-24
WO2010076524A3 (fr) 2010-08-26
EP2382205B1 (fr) 2014-04-23
CR20110361A (es) 2011-09-20
EP2382205A2 (fr) 2011-11-02
PE20120416A1 (es) 2012-05-08
PL2382205T3 (pl) 2014-09-30
MA32976B1 (fr) 2012-01-02
PA8856201A1 (es) 2010-07-27
BRPI0924060A2 (pt) 2015-07-07
EA019591B1 (ru) 2014-04-30
CA2748411A1 (fr) 2010-07-08
ECSP11011155A (es) 2011-07-29
AR074915A1 (es) 2011-02-23
JP5734870B2 (ja) 2015-06-17
SI2382205T1 (sl) 2014-08-29
TN2011000267A1 (fr) 2012-12-17
HRP20140680T1 (hr) 2014-10-10
AU2009334569B2 (en) 2016-02-25
TWI482763B (zh) 2015-05-01
CY1115368T1 (el) 2017-01-04
TW201028391A (en) 2010-08-01
CL2011001496A1 (es) 2011-10-28
SMT201400097B (it) 2014-09-08
NZ593751A (en) 2013-08-30
UY32369A (es) 2010-07-30
DK2382205T3 (da) 2014-07-28
US20110294788A1 (en) 2011-12-01
SG172803A1 (en) 2011-08-29
PT2382205E (pt) 2014-07-28

Similar Documents

Publication Publication Date Title
BRPI0810440A2 (pt) Derivados de triazolopiridina-carboxamidas e triazolopirimidina-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0907381A2 (pt) Derivados de carboxamidas azabicíclicos, o respectivo preparo e a respectiva aplicação em terapêutica.
BRPI1012857A2 (pt) derivados de ciclopenta[c]pirrol-2-carboxilatos, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0810412A2 (pt) Derivados de triazolo piridina-carboxamidas e triazolo pirimidina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0906567A2 (pt) Derivados de ureia de tetra-hidroquinoxalina, o respectivo preparo e a respectiva aplicação em terapêutica j
BRPI0821461A2 (pt) Uso de canabióides em combinação com um medicamento antipsicótico
BRPI0908999A2 (pt) Derivados poli-substituídos de 2-aril-6-imidazo[1,2-a]piridinas, o respectivo preparo e respectiva aplicação em terapêutica
BRPI0907439A2 (pt) Derivado de carboxamidas azabiciclicos, o respectivo preparo e a respectiva aplicação em terapêutica
IL210412A0 (en) Heterocyclic derivatives and uses thereof
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
BRPI0910309A2 (pt) derivados poli-substituídos de 2-aril --fenil-imidazo [1,2-a] piridinas, o respectivo preparo e a respectiva aplicação em terapêtica
IL210514A0 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
BRPI0810430A2 (pt) Derivados de triazolo piridina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI1013553A2 (pt) derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica como anticancerígenos
BR112012000104A2 (pt) derivados de pirazóis, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0917464A2 (pt) compostos de azetidinas polissubstituídas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0907578A2 (pt) derivados de 3-aminoalquil-1,3-di-hidro-2h-indol-2-ona, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0923875A2 (pt) Derivados de 2-piridin-2-il-pirazol-3 (2h)-ona, o respectivo preparo e a respectiva aplicação terapêutica.
ZA201104100B (en) Dimeric avermectin and milbemycin derivatives
BRPI0924060A2 (pt) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicacao em terapeuutica com atividaores de hif
BRPI0923182A2 (pt) derivados de 6-cicloamino-2,3-di-piridinil-imidazo[1,2-b]piridazina, o respectivo preparo e a respectivo preparo e a respectiva aplicação terapêutica
ZA201107363B (en) Quinazolinedione derivatives,preparation thereof and various therapeutic uses thereof
BRPI0821992A2 (pt) Derivados de n-heterocíclico-imidazo[1,2-a]piridina-2-carboxamida s, respectivo preparo e respectiva aplicação em terapêutica
BRPI0821458A2 (pt) Derivado 6-heterocíclico-imidazo[1,2-a]pirroína-2-carboxamida s, o respectivo preparo e a respectiva aplicação em, terapêutica
BRPI0822054A2 (pt) Derivados de azetidinas, o respectivo preparo e a respectiva aplicação em terapêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.